Crown Bioscience's San Diego site fits the tumor model to the therapy, not the reverse
Crown Bioscience's San Diego site designs preclinical tumor models to match specific therapies and delivery routes, rather than forcing treatments into standard study designs. It combines custom surgical procedures, cell line-derived xenografts, patient-derived xenografts (including post-treatment models), and biomarker capabilities to generate translational data that can help sponsors decide whether to advance a program.
This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.
Promoted content from Crown Bioscience on MarketScale.
Key takeaways
Orthotopic brain tumor implantation using tagged models lets researchers track tumor growth in the original organ, aligning the model and delivery route with how therapies are intended to be tested.
Patient-derived xenografts developed from tumors after prior treatment may better reflect progressed disease, helping teams study therapies aimed at patients whose cancer has advanced after earlier treatment.
Combining biomarker analysis of preclinical model samples with clinical sample testing at one site could make it easier to connect what is measured in animals with what is later measured in patients.
Free workspace
Turn your Sciences expertise into content.
Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.
At Crown Bioscience's San Diego site, some brain tumor studies start with the tumor implanted in the brain. According to the site, researchers there have been implanting brain tumors in the brain and then giving treatments directly in that setting. The tumor grows where it would in a patient, and the therapy is tested there, not in a more convenient spot under the skin.
That example sums up what the site offers oncology drug developers. A preclinical model should fit the therapy being tested, including its delivery route, the surgery it needs and the organ it targets. The question for a sponsor is whether a contract research partner can build that fit, and then capture the data needed to decide whether a program moves forward.
Fitting the model to the therapy, not the other way around
The San Diego team says bespoke work is what sets the site apart. New therapies do not always fit standard study designs. A treatment might need a specific surgical procedure, or it might depend on a device or instrument that is part of the therapy itself. The site says it can take on those requirements.
So if you have a particular surgery or a particular instrument that is part of the new therapy that you want to try, we have the skills to do that and adapt to the client's needs. — Christopher Dillon, Crown Bioscience San Diego
Custom procedures only help if there is a suitable tumor to use them on. The site offers cell line-derived xenografts covering a number of tumor indications and says it is adding more. The stated aim is flexibility: clients can pick a tumor model that matches both the treatment and the indication, instead of reshaping their question around whatever models happen to be on the shelf.
A cell line-derived xenograft (CDX) grows an established human cancer cell line in a host animal. A patient-derived xenograft (PDX) comes from a patient's tumor tissue. An orthotopic model places the tumor in the organ it originally came from, such as brain tumor cells implanted in the brain, instead of at a more accessible site.
The orthotopic work depends on many of the site's tumor models being tagged. According to the site, tagging lets researchers place tumors in their original organ and still follow tumor growth there. That matters most in organs where growth is hard to see directly, and the brain is the clearest case.
It is also why the brain tumor work, with implantation and treatment happening in the same place, is the site's lead example. It combines all three pieces: a custom procedure, a matched tumor model and a way to track what happens in the organ that counts.
Patient-derived models, including tumors that have already seen treatment
On patient-derived xenografts, the company says Crown has one of the largest PDX catalogs, covering a variety of indications, including some that are very rare to find. For a team working on an uncommon cancer, whether a relevant model exists at all can decide what gets studied before the clinic.
The site also points to PDX models developed after patients had already received treatment, which it says can help develop "the next wave of therapies." The logic is straightforward. For a program aimed at patients whose disease has progressed after earlier treatment, a model taken from a tumor already exposed to therapy may reflect that group better than a model from an untreated tumor.
Carrying samples from preclinical models to clinical testing
The San Diego site covers in vivo, in vitro and biomarker work, so clients can capture the full set of data they need to advance a project. The site describes itself as a translational biomarker hub: it processes samples from preclinical models and also tests clinical samples.
The biomarker approach is about purpose, not instrument count. "In the biomarker space, we really utilize each platform for its purpose," the site says. That includes flow cytometry, pathology and cytokine detection, each chosen for the scientific question the client is asking. The goal is to hand back insights, not just raw readouts.
Doing both kinds of work in one place could carry a practical benefit. If biomarker work on model samples and on clinical samples happens at the same site, a client may find it easier to connect what was measured in animals with what is later measured in patients.
Why custom work comes down to the people running it
Custom surgery, placing tumors in the organ they came from and dosing directly into the brain all depend on skilled hands. The San Diego site has a mix of PhD scientists and technical staff with bachelor's degrees, drawn from oncology and from fields outside it.
The clearest example of that range is a neuroscientist on staff who informs much of the site's work in brain oncology, including glioblastoma. That ties back to the opening. Implanting and treating tumors in the brain takes knowledge of the brain as well as knowledge of cancer.
The site says its quality rests on a very rigorous training program for research associates. The program is meant to make sure associates are highly skilled, act as stewards of animal welfare and produce the highest-quality data for clients. With nonstandard procedures, where there is no routine to fall back on, that training carries more of the load.
When a therapy depends on a specific route, device or tumor setting, ask a prospective partner to walk through how it tracks tumor growth in that organ and who on staff has done the procedure before. Those two answers say more about reproducibility than a model catalog does.
For drug developers looking for a US onshore testing partner, that is the test San Diego is putting itself up for: can it reproduce a therapy's real conditions reliably? Its answer rests on growing CDX offerings, tagged orthotopic models, post-treatment PDXs and staff trained to run procedures that don't come out of a standard playbook.
Part of this channel
Crown Bioscience
News, updates, and expert insights from Crown Bioscience.
Your experts belong here
Every story in MarketScale Sciences starts with a company putting its lab directors, applications scientists, and field specialists on the record. Buyers are already reading this topic. The only question is whose experts they find.
Lab and research buyers verify before they trial, and your scientists give them something credible to verify against.
About the author
